FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Seibt Matthew

2. Date of Event Requiring Statement (MM/DD/YYYY)
9/18/2019 

3. Issuer Name and Ticker or Trading Symbol

Acer Therapeutics Inc. [ACER]

(Last)        (First)        (Middle)

C/O ACER THERAPEUTICS INC., ONE GATEWAY CENTER, SUITE 351

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                          _____ 10% Owner
___X___ Officer (give title below)        _____ Other (specify below)
Chief Commercial Officer /

(Street)

NEWTON, MA 02458      

(City)              (State)              (Zip)
5. If Amendment, Date Original Filed(MM/DD/YYYY)

 

6. Individual or Joint/Group Filing(Check Applicable Line)

_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person


Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(MM/DD/YYYY)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Employee Stock Option (right to buy)  (1)4/20/2028 Common Stock 12000 $18.53 D  
Employee Stock Option (right to buy)  (2)5/14/2028 Common Stock 13000 $18.11 D  
Employee Stock Option (right to buy)  (3)2/1/2029 Common Stock 11000 $24.46 D  

Explanation of Responses:
(1) The option vests and becomes exercisable over four years as follows: 25% of the shares vested on 04/20/2019, and 1/16th of the shares vest each quarter thereafter for the remaining three years.
(2) The option vests and becomes exercisable over four years as follows: 25% of the shares vested on 05/14/2019, and 1/16th of the shares vest each quarter thereafter for the remaining three years.
(3) The option vests and becomes exercisable over four years as follows: 25% of the shares vested on 02/01/2020, and 1/16th of the shares vest each quarter thereafter for the remaining three years.

Remarks:
Exhibit List: Exhibit 24 Confirming Statement

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Seibt Matthew
C/O ACER THERAPEUTICS INC.
ONE GATEWAY CENTER, SUITE 351
NEWTON, MA 02458


Chief Commercial Officer

Signatures
/s/ Harry Palmin, Attorney-in-fact9/23/2019
**Signature of Reporting PersonDate

Acer Therapeutics (NASDAQ:ACER)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Acer Therapeutics Charts.
Acer Therapeutics (NASDAQ:ACER)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Acer Therapeutics Charts.